Table 3.
Gene Expression Analysis of Xenograft Cells and PLC Cell Line
| Tumor cells by subpopulations | ALB | AFP | α1AT | CK19 | CK7 | CD31 | CD133 | EpCAM | CD44 | CD90 | Major phenotype |
|---|---|---|---|---|---|---|---|---|---|---|---|
| CD34+CD133− | 1.0±0.2 | 1.0±0.2 | 1.0±0.1 | 1.0±0.2 | 1.0±0.1 | 1.0±0.1 | 1.0±0.1 | 1.0±0.1 | 1.0±0.1 | 1.0±0.1 | HCC |
| CD34+CD133+ | 0.7±0.1 | 0.9±0.2 | 2.6±0.3 | 4.5±0.8 | 1.5±0.1 | 0.4±0.1 | 2.9±0.1 | 2.0±0.2 | 1.1±0.1 | 0.4±0.1 | CHC |
| CD34−CD133+ | 145±23 | 1.3±0.1 | 1.3±0.1 | 0.5±0.1 | 0.3±0.1 | 2.4±0.1 | 3.1±0.3 | 4.5±0.4 | 0.2±0.1 | 1.4±0.1 | HCC |
| PLC cell line | 7.6±1.8 | 1.7±0.2 | 2.4±0.2 | 1.0±0.2 | 7.6±1.1 | 2.7±0.5 | 2.1±0.1 | 0.2±0.1 | 0.1±0.1 | 0.3±0.1 | CHC |
| CD34+CD44− | 1.0±0.1 | 1.0±0.1 | 1.0±0.1 | 1.0±0.1 | 1.0±0.1 | 1.0±0.1 | 1.0±0.1 | 1.0±0.1 | 1.0±0.1 | 1.0±0.1 | HCC |
| CD34+CD44+ | 0.5±0.1 | 0.6±0.1 | 0.5±0.2 | 10±1.8 | 18±1.1 | 16±3.0 | 0.3±0.1 | 0.7±0.1 | 15±1.4 | 1.1±0.1 | CHC |
| CD34−CD44+ | 196±49 | 1.4±0.2 | 1.6±0.2 | 2.0±0.2 | 10±0.8 | 118±11 | 0.1±0.1 | 0.2±0.1 | 19±1.8 | 0.1±0.1 | HCC |
| PLC cell line | 3.7±0.9 | 1.6±0.1 | 1.4±0.2 | 2.8±1.3 | 10±1.5 | 1.7±0.3 | 1.1±0.1 | 0.1±0.1 | 0.4±0.1 | 0.1±0.1 | CHC |
| CD34+CD90− | 1.0±0.1 | 1.0±0.1 | 1.0±0.1 | 1.0±0.1 | 1.0±0.1 | 1.0±0.1 | 1.0±0.1 | 1.0±0.2 | 1.0±0.2 | 1.0±0.1 | HCC |
| CD34+CD90+ | 0.6±0.1 | 0.7±0.1 | 1.6±0.3 | 149±28 | 3.5±0.9 | 2.2±0.2 | 0.8±0.1 | 31±4.6 | 0.3±0.1 | 3.9±0.7 | CHC |
| CD34−CD90+ | 2.2±0.2 | 2.0±0.1 | 1.1±0.2 | 0.4±0.1 | 0.6±0.1 | 1.1±0.1 | 4.7±0.8 | 9.2±1.4 | 0.4±0.1 | 1.3±0.2 | HCC |
| PLC cell line | 2.4±0.1 | 0.9±0.1 | 1.2±0.1 | 37±9.4 | 3.1±0.5 | 2.9±0.2 | 1.0±0.2 | 0.1±0.1 | 0.1±0.1 | 0.2±0.1 | CHC |
| CD34+CD31− | 1.0±0.1 | 1.0±0.1 | 1.0±0.1 | 1.0±0.2 | 1.0±0.1 | 1.0±0.1 | 1.0±0.1 | 1.0±0.1 | 1.0±0.1 | 1.0±0.1 | HCC |
| CD34+CD31+ | 0.2±0.1 | 0.7±0.1 | 1.0±0.1 | 60±10 | 4.0±0.7 | 28±3.9 | 0.8±0.1 | 1.0±0.1 | 6.1±0.2 | 1.0±0.1 | CHC |
| CD34−CD31+ | 73±11 | 9.3±1.2 | 2.7±0.8 | 21±3.3 | 10±0.8 | 488±69 | 0.1±0.1 | 0.2±0.1 | 11±0.5 | 0.7±0.1 | CHC |
| PLC cell line | 1.5±0.2 | 3.1±0.9 | 2.6±0.4 | 5.6±1.7 | 2.0±0.1 | 8.2±1.5 | 0.7±0.1 | 0.1±0.1 | 0.1±0.1 | 0.3±0.1 | CHC |
| CD34+EpCAM− | 1.0±0.2 | 1.0±0.1 | 1.0±0.2 | 1.0±0.1 | 1.0±0.1 | 1.0±0.1 | 1.0±0.1 | 1.0±0.1 | 1.0±0.1 | 1.0±0.1 | HCC |
| CD34+EpCAM+ | 0.7±0.1 | 0.6±0.1 | 0.8±0.1 | 35±2.9 | 2.4±0.1 | 0.6±0.1 | 1.8±0.3 | 1.6±0.2 | 1.9±0.1 | 3.4±0.1 | CHC |
| CD34−EpCAM+ | 12±1.4 | 8.1±1.6 | 0.6±0.1 | 0.5±0.1 | 0.2±0.1 | 0.3±0.1 | 1.5±0.2 | 1.3±0.3 | 1.1±0.1 | 1.0±0.1 | HCC |
| PLC cell line | 1.8±0.4 | 2.6±0.8 | 0.9±0.1 | 7.4±2.5 | 3.0±0.6 | 0.5±0.1 | 1.1±0.1 | 0.1±0.1 | 0.2±0.1 | 0.4±0.1 | CHC |
| CD34+OV6− | 1.0±0.1 | 1.0±0.1 | 1.0±0.1 | 1.0±0.2 | 1.0±0.2 | 1.0±0.1 | 1.0±0.2 | 1.0±0.1 | 1.0±0.1 | 1.0±0.1 | HCC |
| CD34+OV6+ | 0.1±0.1 | 0.1±0.1 | 1.0±0.1 | 42±6.9 | 9.6±0.5 | 13±2.1 | 0.4±0.1 | 1.6±0.1 | 14±0.5 | 2.2±0.2 | CHC, CC |
| CD34−OV6+ | 0.1±0.1 | 0.1±0.1 | 2.0±0.1 | 42±5.7 | 48±4.0 | 142±7.6 | 0.1±0.1 | 0.1±0.1 | 62±12 | 1.4±0.3 | CHC, CC |
| PLC cell line | 2.1±0.1 | 2.8±0.1 | 3.9±0.5 | 7.9±1.6 | 8.4±1.2 | 1.5±0.2 | 1.5±0.2 | 0.1±0.1 | 0.4±0.1 | 0.3±0.1 | CHC |
| CD34+ cells | 1.0±0.2 | 1.0±0.1 | 1.0±0.1 | 1.0±0.2 | 1.0±0.2 | 1.0±0.1 | 1.0±0.1 | 1.0±0.1 | 1.0±0.1 | 1.0±0.1 | HCC |
| PLC | 1.1±0.2 | 0.4±0.4 | 1.0±0.1 | 7.5±1.2 | 4.5±0.7 | 1.9±0.3 | 2.0±0.2 | 0.9±0.1 | 0.4±0.1 | 0.8±0.2 | CHC |
| CD34− PLC | 4.1±0.6 | 4.9±1.4 | 1.8±0.4 | 0.6±0.1 | 0.9±0.2 | 0.8±0.1 | 0.2±0.1 | 0.7±0.2 | 0.6±0.1 | 0.5±0.1 | HCC |
| PLC cell line | 1.6±0.3 | 1.2±0.2 | 2.5±0.1 | 2.0±0.2 | 4.9±1.0 | 0.5±0.1 | 1.6±0.1 | 0.1±0.1 | 0.1±0.1 | 0.2±0.1 | CHC |
cDNAs were generated from the cells of xenografts produced by 21 cell populations, and the parental PLC line, and the expression of human liver genes (ALB, AFP, α1-AT, CK19, CK7), liver cancer-related markers (CD133, EpCAM, CD44, CD90), and CD31, were determined by TaqMan PCR. The relative expression levels in each subgroup were normalized to the cells of xenografts produced by the injection of CD34+ negative for CD133, or CD44, or CD31, or CD90, or EpCAM, or OV6 respectively, or by CD34+ cells (bottom of the table). The major phenotype of xenografts produced by each subpopulation is listed at the far right column. Data represent mean±SEM (4≤n≤11).
CC, cholangiocarcinomas; CHC, combined hepatocellular cholangiocarcinoma; HCC, hepatocellular carcinoma.